The first enzyme of fat mobilization — insulin's main antagonist in adipose tissue. Adipose triglyceride lipase (ATGL) opens every stored triglyceride molecule that fasting turns into fuel, working down the lipid droplet one fatty acid at a time together with hormone-sensitive lipase and monoglyceride lipase.
ATGL catalyzes the initial, rate-limiting hydrolysis of a triacylglycerol to a diacylglycerol plus a free fatty acid. The serine hydrolase active site carries a conserved GXSXG motif that attacks the ester bond, releasing the fatty acid and leaving the diacylglycerol for hormone-sensitive lipase, which removes the second acyl chain; monoglyceride lipase finishes the job. The three-step cascade is the lipolytic pathway of fasting.
Regulation
Activated by CGI-58, which is released from perilipin-coated droplets when catecholamines raise cAMP and PKA phosphorylates perilipin — see the cAMP-PKA second messenger pathway.
Suppressed by G0S2, a small protein that binds and inhibits the enzyme directly; feeding raises G0S2.
Insulin shuts the cascade down by lowering cAMP; cortisol and PPAR ligands induce PNPLA2 expression.
Physiological Role
Rate-limiting step of lipolysis: during fasting, ATGL-derived fatty acids feed beta oxidation in liver and muscle and become substrate for ketone body synthesis.
Adipose tissue is an endocrine organ — ATGL activity shapes the circulating fatty acids that tune leptin and adiponectin signaling.
Genetic deficiency (neutral lipid storage disease with myopathy) stacks triglyceride in muscle and liver, showing ATGL is not redundant with HSL.
Interactions
Perilipin-1 and CGI-58 at the white adipocyte lipid droplet organize access to substrate.
Its product diacylglycerol is itself a signaling lipid — see the diacylglycerol entry.
Clinical Relevance
PNPLA2 mutations cause neutral lipid storage disease with myopathy: progressive weakness, cardiomyopathy, and fatty liver from triglyceride the tissue cannot release.
Common PNPLA2 polymorphisms modestly alter lipolysis rate and have been tied to metabolic-syndrome traits in population studies.
Chronically high lipolysis floods the liver with fatty acids and contributes to insulin resistance.
Cancer metabolism research tracks ATGL because several tumors depend on fatty acids released from adipose.